---
document_datetime: 2025-12-29 12:46:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kinzalmono.html
document_name: kinzalmono.html
version: success
processing_time: 0.1378398
conversion_datetime: 2025-12-30 09:02:47.530995
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)

[RSS](/en/individual-human-medicine.xml/67125)

##### Authorised

This medicine is authorised for use in the European Union

telmisartan Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)](#news-on)
- [More information on Kinzalmono](#more-information-on-kinzalmono-873)
- [More information on Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Kinzalmono. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kinzalmono.

Expand section

Collapse section

## What is Kinzalmono?

Kinzalmono is a medicine that contains the active substance telmisartan. It is available as tablets (20, 40 and 80 mg).

## What is Kinzalmono used for?

Kinzalmono is used in adults who have essential hypertension (high blood pressure). 'Essential' means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

## How is Kinzalmono used?

For the treatment of essential hypertension, the usual recommended dose of Kinzalmono is 40 mg once a day, but some patients may benefit from using 20 mg once a day. If the target blood pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.

For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day. The doctor should monitor the patient's blood pressure closely when starting Kinzalmono, and may decide to adjust the patient's blood-pressure-lowering medication. Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day. Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.

## How does Kinzalmono work?

The active substance in Kinzalmono, telmisartan, is an 'angiotensin-II-receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen. This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a stroke.

## How has Kinzalmono been studied?

Kinzalmono has been studied in 1,647 patients who were treated with telmisartan either alone or in combination with hydrochlorothiazide. Kinzalmono was compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine). The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).

## What benefit has Kinzalmono shown during the studies?

Kinzalmono was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.

## What is the risk associated with Kinzalmono?

Side effects with Kinzalmono are not common. However, the following side effects are seen in between 1 and 10 patients in 1,000: upper respiratory tract infection (colds) including inflammation of the throat and sinuses, urinary tract infection (infection of the structures that carry urine) including bladder infection, anaemia (low red blood cell counts), hyperkalaemia (high blood potassium levels), depression, insomnia (difficulty sleeping), syncope (fainting), vertigo (a spinning sensation), bradycardia (slow heart rate), hypotension (low blood pressure), dyspnoea (difficulty breathing), cough, abdominal pain (stomach ache), diarrhoea, dyspepsia (heartburn), flatulence (gas), vomiting, hyperhidrosis (excessive sweating), pruritus (itching), rash, myalgia (muscle pain), back pain, muscle spasms, renal impairment (reduced kidney function) including sudden kidney failure, chest pain, asthenia (weakness) and increased blood levels of creatinine (a marker of muscle breakdown). Hypotension may be more common in patients receiving Kinzalmono to prevent cardiovascular problems. For the full list of all side effects reported with Kinzalmono, see the package leaflet.

Kinzalmono must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is not recommended. Kinzalmono must not be used in people who have severe liver problems or bile problems. In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Kinzalmono must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension). For the full list of restrictions, see the package leaflet.

## Why has Kinzalmono been approved?

The CHMP decided that Kinzalmono's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Kinzalmono?

A risk management plan has been developed to ensure that Kinzalmono is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kinzalmono, including the appropriate precautions to be followed by healthcare professionals and patients.

## Other information about Kinzalmono

The European Commission granted a marketing authorisation valid throughout the European Union for Kinzalmono on 16 December 1998.

For more information about treatment with Kinzalmono, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Kinzalmono : EPAR - Summary for the public

English (EN) (78 KB - PDF)

**First published:** 28/05/2009

**Last updated:** 06/11/2015

[View](/en/documents/overview/kinzalmono-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-624)

български (BG) (110.25 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/bg/documents/overview/kinzalmono-epar-summary-public_bg.pdf)

español (ES) (85.72 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/es/documents/overview/kinzalmono-epar-summary-public_es.pdf)

čeština (CS) (107.79 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/cs/documents/overview/kinzalmono-epar-summary-public_cs.pdf)

dansk (DA) (84.27 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/da/documents/overview/kinzalmono-epar-summary-public_da.pdf)

Deutsch (DE) (88.2 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/de/documents/overview/kinzalmono-epar-summary-public_de.pdf)

eesti keel (ET) (83.94 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/et/documents/overview/kinzalmono-epar-summary-public_et.pdf)

ελληνικά (EL) (113.49 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/el/documents/overview/kinzalmono-epar-summary-public_el.pdf)

français (FR) (86.62 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/fr/documents/overview/kinzalmono-epar-summary-public_fr.pdf)

hrvatski (HR) (102.76 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/hr/documents/overview/kinzalmono-epar-summary-public_hr.pdf)

italiano (IT) (85.02 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/it/documents/overview/kinzalmono-epar-summary-public_it.pdf)

latviešu valoda (LV) (103.89 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/lv/documents/overview/kinzalmono-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (104.54 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/lt/documents/overview/kinzalmono-epar-summary-public_lt.pdf)

magyar (HU) (101.65 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/hu/documents/overview/kinzalmono-epar-summary-public_hu.pdf)

Malti (MT) (108.77 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/mt/documents/overview/kinzalmono-epar-summary-public_mt.pdf)

Nederlands (NL) (85.24 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/nl/documents/overview/kinzalmono-epar-summary-public_nl.pdf)

polski (PL) (108.21 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/pl/documents/overview/kinzalmono-epar-summary-public_pl.pdf)

português (PT) (86.06 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/pt/documents/overview/kinzalmono-epar-summary-public_pt.pdf)

română (RO) (103.62 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/ro/documents/overview/kinzalmono-epar-summary-public_ro.pdf)

slovenčina (SK) (107.23 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/sk/documents/overview/kinzalmono-epar-summary-public_sk.pdf)

slovenščina (SL) (102.39 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/sl/documents/overview/kinzalmono-epar-summary-public_sl.pdf)

Suomi (FI) (84.35 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/fi/documents/overview/kinzalmono-epar-summary-public_fi.pdf)

svenska (SV) (84.82 KB - PDF)

**First published:**

28/05/2009

**Last updated:**

06/11/2015

[View](/sv/documents/overview/kinzalmono-epar-summary-public_sv.pdf)

## Product information

Kinzalmono : EPAR - Product Information

English (EN) (569.41 KB - PDF)

**First published:** 16/06/2009

**Last updated:** 23/04/2025

[View](/en/documents/product-information/kinzalmono-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-604)

български (BG) (716.21 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/bg/documents/product-information/kinzalmono-epar-product-information_bg.pdf)

español (ES) (605.45 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/es/documents/product-information/kinzalmono-epar-product-information_es.pdf)

čeština (CS) (692.96 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/cs/documents/product-information/kinzalmono-epar-product-information_cs.pdf)

dansk (DA) (596.42 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/da/documents/product-information/kinzalmono-epar-product-information_da.pdf)

Deutsch (DE) (610.99 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/de/documents/product-information/kinzalmono-epar-product-information_de.pdf)

eesti keel (ET) (597.08 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/et/documents/product-information/kinzalmono-epar-product-information_et.pdf)

ελληνικά (EL) (703.64 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/el/documents/product-information/kinzalmono-epar-product-information_el.pdf)

français (FR) (681.98 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/fr/documents/product-information/kinzalmono-epar-product-information_fr.pdf)

hrvatski (HR) (645.73 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/hr/documents/product-information/kinzalmono-epar-product-information_hr.pdf)

íslenska (IS) (608.14 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/is/documents/product-information/kinzalmono-epar-product-information_is.pdf)

italiano (IT) (646.03 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/it/documents/product-information/kinzalmono-epar-product-information_it.pdf)

latviešu valoda (LV) (645.45 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/lv/documents/product-information/kinzalmono-epar-product-information_lv.pdf)

lietuvių kalba (LT) (658.31 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/lt/documents/product-information/kinzalmono-epar-product-information_lt.pdf)

magyar (HU) (660.78 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/hu/documents/product-information/kinzalmono-epar-product-information_hu.pdf)

Malti (MT) (758.94 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/mt/documents/product-information/kinzalmono-epar-product-information_mt.pdf)

Nederlands (NL) (633.8 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/nl/documents/product-information/kinzalmono-epar-product-information_nl.pdf)

norsk (NO) (586.45 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/no/documents/product-information/kinzalmono-epar-product-information_no.pdf)

polski (PL) (707.28 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/pl/documents/product-information/kinzalmono-epar-product-information_pl.pdf)

português (PT) (602.72 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/pt/documents/product-information/kinzalmono-epar-product-information_pt.pdf)

română (RO) (711.19 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/ro/documents/product-information/kinzalmono-epar-product-information_ro.pdf)

slovenčina (SK) (725.69 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/sk/documents/product-information/kinzalmono-epar-product-information_sk.pdf)

slovenščina (SL) (686.47 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/sl/documents/product-information/kinzalmono-epar-product-information_sl.pdf)

Suomi (FI) (598.81 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/fi/documents/product-information/kinzalmono-epar-product-information_fi.pdf)

svenska (SV) (592.38 KB - PDF)

**First published:**

16/06/2009

**Last updated:**

23/04/2025

[View](/sv/documents/product-information/kinzalmono-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000242970 03/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kinzalmono : EPAR - All Authorised presentations

English (EN) (15.28 KB - PDF)

**First published:** 23/01/2007

**Last updated:** 23/01/2007

[View](/en/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-535)

български (BG) (103.5 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/bg/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_bg.pdf)

español (ES) (15.56 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/es/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/cs/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.38 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/da/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (15.43 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/de/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.42 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/et/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (99.52 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/el/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_el.pdf)

français (FR) (15.65 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/fr/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (28.09 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/hr/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (28 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/is/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_is.pdf)

italiano (IT) (15.15 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/it/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (98.37 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/lv/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (102.26 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/lt/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (99.98 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/hu/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.7 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/mt/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.09 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/nl/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (28.97 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/no/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_no.pdf)

polski (PL) (55.55 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/pl/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.36 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/pt/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_pt.pdf)

română (RO) (97.3 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/ro/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (55.36 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/sk/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (51.76 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/sl/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (15.6 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/fi/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.57 KB - PDF)

**First published:**

23/01/2007

**Last updated:**

23/01/2007

[View](/sv/documents/all-authorised-presentations/kinzalmono-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG) Active substance telmisartan International non-proprietary name (INN) or common name telmisartan Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA07

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

**Hypertension**

Treatment of essential hypertension in adults.

**Cardiovascular prevention**

Reduction of cardiovascular morbidity in patients with:

- manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;
- type-2 diabetes mellitus with documented target-organ damage.

## Authorisation details

EMA product number EMEA/H/C/000211 Marketing authorisation holder

Bayer AG

51368 Leverkusen Germany

Opinion adopted 23/07/1998 Marketing authorisation issued 16/12/1998 Revision 32

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kinzalmono : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.02 KB - PDF)

**First published:** 23/04/2025

[View](/en/documents/procedural-steps-after/kinzalmono-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kinzalmono : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (317.11 KB - PDF)

**First published:** 25/06/2009

**Last updated:** 23/04/2025

[View](/en/documents/procedural-steps-after/kinzalmono-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)-H-C-211-A31-0094 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 03/10/2014

**Last updated:** 03/10/2014

[View](/en/documents/variation-report/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-assessment-report-article-31_en.pdf)

Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)-H-C-211-A31-0094 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scie...

English (EN) (48.81 KB - PDF)

**First published:** 03/10/2014

**Last updated:** 03/10/2014

[View](/en/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_en.pdf)

[Other languages (22)](#file-language-dropdown-325)

български (BG) (87.49 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/bg/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/es/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/cs/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/da/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/de/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/et/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/el/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/fr/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/hr/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/it/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/lv/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/lt/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/hu/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/mt/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/nl/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/pl/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/pt/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/ro/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/sk/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/sl/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/fi/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

03/10/2014

**Last updated:**

03/10/2014

[View](/sv/documents/scientific-conclusion/kinzalmono-previously-telmisartan-boehringer-ingelheim-pharma-kg-h-c-211-a31-0094-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scie_sv.pdf)

CHMP post-authorisation summary of positive opinion for Kinzalmono

Adopted

Reference Number: EMA/CHMP/261191/2013

English (EN) (66.57 KB - PDF)

**First published:** 26/04/2013

**Last updated:** 26/04/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kinzalmono_en.pdf)

Kinzalmono-H-C-211-WS-0254 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/549534/2012

English (EN) (547.44 KB - PDF)

**First published:** 28/02/2013

**Last updated:** 28/02/2013

[View](/en/documents/variation-report/kinzalmono-h-c-211-ws-0254-epar-assessment-report-variation_en.pdf)

Kinzalmono-H-C-211-II-0072 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/768467/2009

English (EN) (1.09 MB - PDF)

**First published:** 08/02/2010

**Last updated:** 08/02/2010

[View](/en/documents/variation-report/kinzalmono-h-c-211-ii-0072-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Kinzalmono on 22 October 2009

Adopted

Reference Number: EMEA/CHMP/681835/2009

English (EN) (30.26 KB - PDF)

**First published:** 22/10/2009

**Last updated:** 22/10/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-kinzalmono-22-october-2009_en.pdf)

Kinzalmono : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (98.6 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/steps-after-cutoff/kinzalmono-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Kinzalmono : EPAR - Scientific Discussion

English (EN) (238.79 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/scientific-discussion/kinzalmono-epar-scientific-discussion_en.pdf)

Kinzalmono : EPAR - Procedural steps taken before authorisation

English (EN) (92.44 KB - PDF)

**First published:** 10/07/2006

**Last updated:** 10/07/2006

[View](/en/documents/procedural-steps/kinzalmono-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2013) 26/04/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

[European Medicines Agency recommendation on use of angiotensin-II-receptor antagonists during pregnancy](/en/news/european-medicines-agency-recommendation-use-angiotensin-ii-receptor-antagonists-during-pregnancy) 24/04/2008

#### More information on Kinzalmono

- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

#### More information on Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 23/04/2025

## Share this page

[Back to top](#main-content)